US 12,337,003 B2
Pharmaceutical compositions for combination therapy
Mark Pruzanski, New York, NY (US); and Luciano Adorini, Milan (IT)
Assigned to Intercept Pharmaceuticals, Inc., Morristown, NJ (US)
Filed by Intercept Pharmaceuticals, Inc., Morristown, NJ (US)
Filed on Mar. 21, 2022, as Appl. No. 17/700,317.
Application 17/700,317 is a continuation of application No. 15/548,537, granted, now 11,311,557, previously published as PCT/US2016/016694, filed on Feb. 5, 2016.
Claims priority of provisional application 62/113,134, filed on Feb. 6, 2015.
Prior Publication US 2022/0280533 A1, Sep. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/575 (2006.01); A61K 31/192 (2006.01); A61K 31/216 (2006.01); A61K 31/366 (2006.01); A61K 31/40 (2006.01); A61K 31/451 (2006.01); A61K 31/56 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/575 (2013.01) [A61K 31/192 (2013.01); A61K 31/216 (2013.01); A61K 31/366 (2013.01); A61K 31/40 (2013.01); A61K 31/451 (2013.01); A61K 31/56 (2013.01); A61K 45/06 (2013.01)] 18 Claims
 
1. A pharmaceutical composition comprising a combination of a compound of formula (1):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or amino acid conjugate thereof, and bezafibrate; and optionally one or more pharmaceutically acceptable carriers, wherein bezafibrate is in an amount of 80-400 mg; and
wherein the compound of formula (1) or pharmaceutically acceptable salt or amino acid conjugate thereof is in an amount of about 5 mg or about 10 mg.